orega PNGorega PNGorega PNGorega PNG
  • Home
  • About us
  • Pipeline
  • News
  • Contact
✕

Orphelia pharma DISCOVERY. Translating cancer science into novel immunotherapies Orphelia pharma SCIENCE. Reveal unexplored regulators of anticancer immunity

Latest news and report

  • 17 April 2026

    Interim results from IPH5201 phase 2 trial (AACR 2026)


    Read more
  • 6 April 2026

    AACR annual meeting 2026


    Read more
  • 21 June 2024

    CICON 2024


    Read more
  • 26 June 2023

    First patient dosed in phase 2 MATISSE trial of IPH5201


    Read more
  • 10 April 2023

    AACR annual meeting 2023


    Read more
  • 24 February 2023

    IPH5201 (CD39 mAb): initiation of Phase 2 clinical trial MATISSE


    Read more
  • 23 December 2022

    Happy holidays and Merry Christmas !


    Read more
  • 6 December 2022

    OREGA enters into a License Agreement with Genmab


    Read more
OREGA Biotech - 15 ch. du Saquin, bât. G, F-69130 Ecully
Phone : +33 4 37 49 87 20 – orega@orega-biotech.com
      Home
      This website uses cookies to improve your experience. By using this website you agree to our Data Protection Policy.
      Read more